e-learning
resources
Amsterdam 2011
Sunday, 25.09.2011
Immunobiology in the transplanted lung: experimental and clinical evaluations
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparison between SCOT-15® and Perfadex® as lung preservation solutions
A. Olland, C. Meers, M. Benahmed, K. Elbayed, S. Wauters, E. Verbeken, G. Verleden, I. Namer, D. Van Raemdonck (Leuven, Belgium; Strasbourg, France)
Source:
Annual Congress 2011 - Immunobiology in the transplanted lung: experimental and clinical evaluations
Session:
Immunobiology in the transplanted lung: experimental and clinical evaluations
Session type:
Oral Presentation
Number:
222
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Olland, C. Meers, M. Benahmed, K. Elbayed, S. Wauters, E. Verbeken, G. Verleden, I. Namer, D. Van Raemdonck (Leuven, Belgium; Strasbourg, France). Comparison between SCOT-15® and Perfadex® as lung preservation solutions. Eur Respir J 2011; 38: Suppl. 55, 222
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Nasal high-Flow (NHF) improves ventilation in patients with interstitial lung disease (ILD)
Noninvasive negative pressure ventilation improves survival of COPD patients with exercise desaturation
Cerebral oxygenation in lowlanders with COPD spending a night at 2590m
Related content which might interest you:
Optimization of inhalation treatment – Evaluation of influence of PNEUMOlogic® and Optimiser® spacers on aerosol particle distribution from pMDI-EB
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011
Evaluation of pulmonary diffusion: TL
CO
or K
CO
?
Source: Annual Congress 2010 - Advances in lung function I
Year: 2010
Ways to shorten the lung clearance index measurement ΙΙ – How long to wash?
Source: Annual Congress 2012 - New developments in paediatric respiratory physiology
Year: 2012
Usability evaluation of NEXThaler® versus Diskus® and Turbuhaler®
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
Patient assessments of ease of use of Genuair® versus Aerolizer® and HandiHaler®
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011
Transcutaneous measurement of pCO
2
(p
tc
CO
2
): Time delay from change in alveolar pCO
2
to first response in p
tc
CO
2
Source: Annual Congress 2011 - Sleep and weight: heavy under pressure
Year: 2011
Alterations in
ORMDL
expression in experimental esthma
Source: Annual Congress 2012 - Mechanisms and risk of childhood asthma and allergy
Year: 2012
Airway resistances: R
aw
, sR
aw
, sR
eff
– Which is the best determinant of airway function?
Source: Annual Congress 2010 - Lung function from infancy to adulthood
Year: 2010
LungPoint® – A new approach to peripheral lung lesions
Source: Annual Congress 2010 - Tissue is mostly the issue: diagnostic and therapeutic bronchoscopy
Year: 2010
Optimization of inhalation treatment – Assessment of the influence of diluent and air humidity on particle distribution of colistin administered by BCTS method [bronchial control treatment system]
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010
Curette lavage fluid analysis of
EGFR
,
KRAS
, and
P53
mutations in lung cancer patients
Source: Annual Congress 2011 - Progress in endoscopy for the diagnosis of lung cancer
Year: 2011
Postoperative predicting value of lung function in patients with lung cancer – Fortune-telling or reality? Evaluation after surgical treatment
Source: Annual Congress 2011 - Lung function today and tomorrow II
Year: 2011
Clinical decision making in alpha
1
antitrypsin deficiency emphysema – Methodologies to determine individual rates of FEV
1
decline
Source: Annual Congress 2010 - Novel biomarkers and old parameters in approaching pulmonary diseases
Year: 2010
Detection of lung cancer on CXR – A comparison of radiologist‘s performance
Source: Annual Congress 2010 - Quality management for lung cancer patients
Year: 2010
Study of the use of Chartis® pulmonary assessment system to optimize subject selection for endobronchial lung volume reduction (ELVR) – Results and subgroup analysis
Source: Annual Congress 2011 - Endoscopic lung volume reduction: hype or hope?
Year: 2011
Double tracer gas single breath washout – Comparison with conventional lung function tests in children with and without cystic fibrosis
Source: Annual Congress 2011 - Advances in lung function testing from infancy to adulthood
Year: 2011
EGFR
,
HER2
and
KRAS
mutational status according to adenocarcinoma patterns/sub-types
Source: Annual Congress 2011 - Genetics of airway diseases and treatment
Year: 2011
Ways to shorten the lung clearance index measurement I – Are three measurements needed?
Source: Annual Congress 2012 - New understanding of childhood lung disease through physiological measurement
Year: 2012
The results of drug resistance survey of MDR-strains on second line drugs obtains in national reference laboratory – " M.Nasta " Institute – Bucharest
Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2011
Clinical evaluation in 14 cases of diffuse alveolar hemorrhage – Relationship between initial findings and prognosis –
Source: Annual Congress 2010 - Rare diffuse lung diseases
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept